PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,866,626 | +149.5% | 169,311 | +108.3% | 0.00% | – |
Q1 2024 | $2,351,141 | +40.6% | 81,270 | +11.4% | 0.00% | – |
Q4 2023 | $1,672,307 | +160.4% | 72,931 | +89.4% | 0.00% | – |
Q3 2023 | $642,280 | +6.6% | 38,506 | +76.6% | 0.00% | – |
Q2 2023 | $602,365 | -53.4% | 21,809 | -61.2% | 0.00% | -100.0% |
Q1 2023 | $1,292,968 | +112.0% | 56,216 | +0.6% | 0.00% | – |
Q4 2022 | $609,770 | +600.9% | 55,891 | +443.2% | 0.00% | – |
Q3 2022 | $87,000 | -71.0% | 10,289 | -72.9% | 0.00% | – |
Q2 2022 | $300,000 | -58.7% | 37,956 | +23.6% | 0.00% | – |
Q1 2022 | $727,000 | -81.5% | 30,700 | -73.2% | 0.00% | -100.0% |
Q4 2021 | $3,922,000 | +282.6% | 114,696 | +98.3% | 0.00% | – |
Q3 2021 | $1,025,000 | +251.0% | 57,854 | +299.7% | 0.00% | – |
Q4 2020 | $292,000 | +12.7% | 14,473 | +9.1% | 0.00% | – |
Q3 2020 | $259,000 | +197.7% | 13,268 | +2.5% | 0.00% | – |
Q2 2018 | $87,000 | -62.5% | 12,945 | +18.1% | 0.00% | -100.0% |
Q3 2016 | $232,000 | – | 10,964 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |